

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 110807015, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: June 19, 2003

Signature:

Richard Zimmermann
(Richard Zimmermann)

Docket No.: 29915/6280M
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark E. Gurney, et al.

Application No.: 09/869,414

Group Art Unit: 1647

Filed: June 27, 2001

Examiner: C. Nicholas

For: **ALZHEIMER'S DISEASE SECRETASE, APP
SUBSTRATES THEREFOR, AND USES
THEREFOR**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The above-identified application is a member of a family of co-pending U.S. applications (the "Asp2" applications). This Information Disclosure Statement describes the family of applications for the Examiner.

I. Prosecution Strategy

A multi-application filing strategy was initiated to expedite prosecution of the Asp2 patent applications. Petitions to make special require restriction to a single invention. It was predicted that the originally filed claims in 09/416,901 would be restricted into at least 5 claim groups (human Asp2 polynucleotides, human Asp2 polypeptides, methods of screening, murine Asp2 polynucleotide and polypeptide sequences, and methods of using antisense oligonucleotides). Therefore, 10 divisional applications were filed in April, 2000 wherein these 5 claim groups were each presented in two divisional applications. Petitions to make special were filed in five of the divisional applications (one for each claim set). Because of antidotal evidence that petitions to make special will sometimes actually slow prosecution, five identical applications were filed without petitions.

The American Inventor's Protection Act of November 29, 2000 created new provisional rights in the United States based on a published application. Therefore, five additional divisional applications were filed in February, 2001 for the purpose of publication in the United States. Since the speed at which the U.S. PTO would publish these applications was uncertain, three PCT applications were filed with the International Bureau with a request for expedited publication in May, 2001. These steps were taken to have an application publish and be effective in the U.S. for provisional rights as soon as possible.

II. Related Pending Applications

Submitted herewith, as Appendix A and Form PTO-1449, is list of pending U.S. patent applications that are related to the above-identified application. The related applications claim priority to U.S. provisional applications 60/101,594 and 60/155,493, and U.S. application 09/404,133 (abandoned). One or more of the related applications may contain claims that are similar in scope or content to claims of the present application. Copies of these applications are not enclosed, but are pending in the U.S. Patent Office and should be available to the Examiner.

These pending applications are currently under examination by Examiners Sharon Turner, Olga Chernyshev or Elizabeth Slobodyansky. Examiners Turner and Chernyshev, both of whom have examined multiple applications of the family, have been made aware of the size and complexity of the patent family on an informal basis. As this is the present examiner's first exposure to the patent family, this statement is submitted to assist him in understanding the patent family.

The elected claims in the present invention are directed to polynucleotides of SEQ ID NO: 3, the polypeptides (SEQ ID NO: 4) encoded thereby and methods of using these polynucleotides and polypeptides. The following related pending U.S. applications contain claims directed to SEQ ID NO: 3, SEQ ID NO: 4 and/or methods of screening using the polynucleotides or polypeptides: 09/548,368, 09/548,365, 09/548,366, 09/549,369, 09/794,743, 09/794,927, 09/794,847, and 09/794,925.

During the course of prosecution of these applications, different examiners have raised a variety of rejections under 35 U.S.C. §102, §103, §112, first and second paragraphs, and double patenting. Upon request, the Applicants will provide the Examiner with copies of office actions and/or responses filed for the related applications. The

Application No.: 09/869,414


Examiner is invited to contact the undersigned if further explanation of the patent family is necessary.

III. Conclusion

This Statement is filed prior to receipt of a first Office Action on the merits, and consequently should be considered by the Patent Office without payment of a fee according to 37 C.F.R. §1.97(b)(3). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855.

Dated: June 19, 2003

Respectfully submitted,

By 
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agents for Applicant

APPENDIX A
RELATED PENDING U.S. PATENT APPLICATIONS

<u>Serial Number</u>	<u>Filing Date</u>	<u>Examiner</u>	<u>Relationship</u>	<u>Elected Subject Matter</u>
09/416,901	10/13/99	Turner	CIP of 09/404,133	Asp2 polypeptide fragments of SEQ ID NO: 6 (aa. 93-266)
09/548,373	4/12/00	Turner	Divisional of 09/416,901	Asp2 polypeptides - full length and fragments of SEQ ID NO: 6
09/548,368	4/12/00	Turner	Divisional of 09/416,901	Asp2 polypeptides - fragments of SEQ ID NO: 4
09/548,370	4/12/00	Turner	Divisional of 09/416,901	Asp2 polynucleotides encoding full length and fragments of SEQ ID NO: 4
09/548,365	4/12/00	Turner	Divisional of 09/416,901	Asp2 polynucleotides encoding fragments of SEQ ID NO: 4 (aa. 93-291)
09/548,376	4/12/00	Chernyshev	Divisional of 09/416,901	Methods of screening for modulators of Asp2 activity using polypeptides of SEQ ID NO: 6
09/548,369 (abandoned)	4/12/00	Turner	Divisional of 09/416,901	Methods of screening for modulators of Asp2 activity using polypeptides of SEQ ID NO: 4
09/548,366	4/12/00	Turner	Divisional of 09/416,901	Full length Asp2 polynucleotides encoding SEQ ID NO: 4
09/794,743	2/27/01	Slobodyansky	Divisional of 09/416,901	Asp2 polypeptide fragments of SEQ ID NO: 4

<u>Serial Number</u>	<u>Filing Date</u>	<u>Examiner</u>	<u>Relationship</u>	<u>Elected Subject Matter</u>
09//795,847	2/28/01	Chernyshev	Divisional of 09/416,901	Asp2 polynucleotides encoding fragments of SEQ ID NO: 4
09/794,927	2/27/01	Chernyshev	Divisional of 09/416,901	Methods of screening for modulators of Asp2 activity using SEQ ID NOS: 3 and 4
09/794,925	2/27/01	Chernyshev	Divisional of 09/416,901	Asp2 full length polypeptide of SEQ ID NO: 4
09/794,748	2/27/01	McGerry	Divisional of 09/416,901	Methods of using Asp2 Antisense Oligonucleotides
09/806,194	3/23/01	Nicholas	National phase filing of PCT/US00/20881	All Asp1 and Asp2 claims

Form PTO-1449 (Modified)

Atty. Docket No.
29915/6280MSerial No.
09/869,414**INFORMATION DISCLOSURE STATEMENT**Applicant(s)
Gurney, et al.Filing Date
June 27, 2001Art Unit
1647**RECEIVED**

JUN 24 2003

U.S. PATENT DOCUMENTS**TECH CENTER 1600'**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
	09/416,901		Gurney, et al.			10/13/1999
	09/548,373		Gurney, et al.			04/12/2000
	09/548,368		Gurney, et al.			04/12/2000
	09/548,370		Gurney, et al.			04/12/2000
	09/548,365		Gurney, et al.			04/12/2000
	09/548,376		Gurney, et al.			04/12/2000
	09/548,369		Gurney, et al.			04/12/2000
	09/548,366		Gurney, et al.			04/12/2000
	09/794,743		Gurney, et al.			02/27/2001
	09/795,847		Gurney, et al.			02/28/2001
	09/794,927		Gurney, et al.			02/27/2001
	09/794,925		Gurney, et al.			02/27/2001
	09/794,748		Gurney, et al.			02/27/2001
	09/806,194		Gurney, et al.			03/23/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No

OTHER DOCUMENTS

EXAMINER:

DATE CONSIDERED: